News

2

Nov, 2016

The ZIKAction Kick-Off Meeting was a success!

Tags:

The ZIKAction Kick-Off Meeting was held in Kingston, Jamaica at the University of West Indies from October 30th to November 1st. Thank you all for coming!! This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734857.

READ MORE

21

Oct, 2016

PENTA Foundation coordinated ZIKAction consortium

Tags:

PENTA Foundation coordinated ZIKAction consortium awarded €7 million EU H2020 grant to combat Zika virus and other emerging infectious disease outbreaks The ZIKAction consortium (Preparedness, research and action network on maternal-paediatric axis of Zika virus infection in Latin America and the Caribbean), coordinated by the PENTA Foundation, is set to receive a €7 million, five-year grant from the European Union through the Horizon 2020 programme’s recent call for research to combat Zika virus (ZIKV) and other emerging infections transmitted by mosquitoes in Latin America. This award is one of three […]

READ MORE

21

Sep, 2016

PENTA 2016 Guidelines

 

Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with HIV The paper: Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with HIV is now published. Click here to see the article

READ MORE

14

Jul, 2015

Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission

 

Authors: Klein N, Palma P, Luzuriaga K, et al. Published in: Lancet Infect Dis. 2015;15(9):1108-1114. Abstract: From the use of antiretroviral therapy to prevent mother-to-child transmission to the possibility of HIV cure hinted at by the Mississippi baby experience, paediatric HIV infection has been pivotal to our understanding of HIV pathogenesis and management. Daily medication and indefinite antiretroviral therapy is recommended for children infected with HIV. Maintenance of life-long adherence is difficult and the incidence of triple-class virological failure after initiation of antiretroviral therapy increases with time. This challenge shows the urgent need to define novel strategies to provide long-term viral suppression that will allow safe interruption of antiretroviral therapy without viral rebound and any associated complications. HIV-infected babies treated within […]

READ MORE